06:11 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Aug. 6 after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan...
18:34 , Aug 6, 2018 |  BC Extra  |  Company News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Monday after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan to...
18:59 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Pain reports Phase I data for AD candidate PTI-125

In October, Pain Therapeutics Inc. (NASDAQ:PTIE) reported data from a Phase I trial of Alzheimer's disease candidate PTI-125 in 24 healthy volunteers showing that single oral doses of 50, 100 and 200 mg were well...
07:00 , Apr 14, 2016 |  BC Innovations  |  Product R&D

AACR by the numbers

See Figure: Top indications See Table: Novel cancer targets at AACR 2016 See Figure: Top institutions and companies See Figure: Top targets Tables Novel cancer targets at...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Filamin A (FLNA); regulator of calcineurin 1 (RCAN1; DSC1)

Neurology INDICATION: Neurology Rat studies suggest FLNA could help treat periventricular heterotopia (PH) caused by a deficiency in RCAN1. In rats, shRNA knockdown of RCAN1 in the brain decreased FLNA levels and neuronal migration and increased formation...
08:00 , Dec 17, 2012 |  BioCentury  |  Finance

Pain gives back

Pain gives back Pain Therapeutics Inc. (NASDAQ:PTIE) believes payments for pain candidate Remoxy from partner Pfizer Inc. (NYSE:PFE) and its existing cash give the biotech more than enough runway to move an Alzheimer's disease diagnostic to...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Pain Therapeutics Inc. preclinical data

In a mouse model of AD and in brain tissue from deceased AD patients, PTI-125 suppressed the toxic effects of beta amyloid. Pain said that by binding to filamin A (FLNA), PTI-125 prevents...
07:00 , Jul 12, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Membrane proteins anchored by glycosylphosphatidylinositol as markers of breast carcinomas Membrane proteins anchored by glycosylphosphatidylinositol could be useful markers of...
07:00 , May 3, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Osteoarthritis Filamin A (FLNA); core-binding factor b-subunit (CBFB; CBFb) In vitro and mouse studies suggest the...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

Novartis preclinical data

In collagenase- and surgery-induced mouse models of OA, kartogenin promoted cartilage repair. Additionally, 1, 10 and 100 µM doses of the small molecule inhibitor of filamin A (FLNA) that promotes chondrocyte differentiation significantly reduced...